Stoke Therapeutics, Inc. (STOK)
Largest Insider Buys in Sector
STOK Stock Price History Chart
STOK Stock Performance
About Stoke Therapeutics, Inc.
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the …
Insider Activity of Stoke Therapeutics, Inc.
Over the last 12 months, insiders at Stoke Therapeutics, Inc. have bought $0 and sold $72.86M worth of Stoke Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Stoke Therapeutics, Inc. have bought $29.25M and sold $19.11M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 375,000 shares for transaction amount of $14.63M was made by Harrison Seth Loring () on 2020‑11‑24.
List of Insider Buy and Sell Transactions, Stoke Therapeutics, Inc.
| 2024-11-01 | Sale | CHIEF MEDICAL OFFICER | 10,000 0.0187% | $12.68 | $126,803 | +1.87% | ||
| 2024-10-01 | Sale | CHIEF MEDICAL OFFICER | 10,000 0.0187% | $12.06 | $120,648 | +0.24% | ||
| 2024-09-19 | Sale | 10 percent owner | 1.94M 3.4152% | $14.05 | $27.22M | -18.20% | ||
| 2024-09-03 | Sale | CHIEF MEDICAL OFFICER | 10,000 0.0189% | $14.95 | $149,481 | -14.44% | ||
| 2024-08-01 | Sale | CHIEF MEDICAL OFFICER | 10,000 0.019% | $14.58 | $145,843 | -6.73% | ||
| 2024-07-02 | Sale | Chief Business Officer | 2,500 0.0049% | $13.11 | $32,779 | 0.00% | ||
| 2024-07-01 | Sale | CHIEF MEDICAL OFFICER | 10,000 0.0204% | $13.75 | $137,458 | 0.00% | ||
| 2024-06-03 | Sale | CHIEF MEDICAL OFFICER | 10,000 0.0189% | $15.22 | $152,185 | -8.30% | ||
| 2024-05-20 | Sale | CEO | 42,350 0.0779% | $15.43 | $653,529 | -11.67% | ||
| 2024-05-20 | Sale | GENERAL COUNSEL & CORP SEC | 8,599 0.0154% | $15.04 | $129,327 | -11.67% | ||
| 2024-05-20 | Sale | COO & CBO | 50,000 0.0917% | $15.39 | $769,500 | -11.67% | ||
| 2024-05-01 | Sale | CHIEF MEDICAL OFFICER | 10,000 0.0189% | $11.37 | $113,653 | +21.43% | ||
| 2024-04-17 | Sale | 10 percent owner | 3.6M 6.8708% | $11.60 | $41.76M | +18.17% | ||
| 2024-04-01 | Sale | CHIEF MEDICAL OFFICER | 9,426 0.02% | $13.23 | $124,684 | +1.71% | ||
| 2024-04-01 | Sale | COO & CBO | 61,329 0.1299% | $13.23 | $811,212 | +1.71% | ||
| 2024-03-28 | Sale | GENERAL COUNSEL & CORP SEC | 5,126 0.0108% | $13.20 | $67,668 | +1.56% | ||
| 2024-03-19 | Sale | CEO | 11,150 0.0263% | $6.10 | $67,999 | +136.66% | ||
| 2024-03-19 | Sale | CFO | 4,116 0.0097% | $6.10 | $25,102 | +136.66% | ||
| 2024-03-19 | Sale | CHIEF MEDICAL OFFICER | 4,116 0.0097% | $6.10 | $25,102 | +136.66% | ||
| 2024-03-19 | Sale | COO & CBO | 4,116 0.0097% | $6.10 | $25,102 | +136.66% |
Insider Historical Profitability
| Harrison Seth Loring | 17161713 32.5972% | $13.32 | 2 | 0 | <0.0001% | |
| Apple Tree Partners IV, L.P. | 10 percent owner | 17161713 32.5972% | $13.32 | 2 | 0 | <0.0001% |
| RTW INVESTMENTS, LP | 10 percent owner | 3544248 6.732% | $13.32 | 6 | 1 | <0.0001% |
Institutional Investor Ownership
| Skorpios Trust | $194.99M | 27.71 | 14.44M | 0% | +$0 | 99.92 | |
| Redmile Group | $68.49M | 9.73 | 5.07M | +93.22% | +$33.04M | 0.7 | |
| RTW Investments, LP | $57.04M | 8.11 | 4.22M | +2.27% | +$1.27M | 0.85 | |
| Morgan Stanley | $54.34M | 7.72 | 4.03M | +19.42% | +$8.84M | <0.01 | |
| BlackRock | $52.09M | 7.4 | 3.86M | +87.28% | +$24.28M | <0.01 |